174 related articles for article (PubMed ID: 24727596)
1. Association between hypoglycemia and the type of insulin in diabetic patients treated with multiple injections: an observational study.
Wróbel MP; Wystrychowski G; Psurek A; Szymborska-Kajanek A; Strojek K
Pol Arch Med Wewn; 2014; 124(4):173-9. PubMed ID: 24727596
[TBL] [Abstract][Full Text] [Related]
2. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
Pala L; Dicembrini I; Mannucci E
Acta Diabetol; 2019 Sep; 56(9):973-980. PubMed ID: 30945047
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, open-label, nonrandomized, observational safety study in subjects using insulin aspart in basal-bolus regimen for the treatment of diabetes.
Krzymień J; Kobli T; Nazar M
Pol Arch Med Wewn; 2010 Nov; 120(11):444-50. PubMed ID: 21102380
[TBL] [Abstract][Full Text] [Related]
4. A bridge to insulin pump therapy: twice-daily regimen with NPH and detemir insulins during initial treatment of youth with type 1 diabetes mellitus.
Cengiz E; Sherr JL; Erkin-Cakmak A; Weinzimer SA; Burke EN; Sikes KA; Urban AD; Tamborlane WV
Endocr Pract; 2011; 17(6):862-6. PubMed ID: 21550949
[TBL] [Abstract][Full Text] [Related]
5. Hypoglycemia observed during continuous glucose monitoring in patients with type 2 diabetes mellitus treated by subcutaneous insulin injection.
Ito H; Abe M; Shinozaki M; Oshikiri K; Yamashita H; Nakashima M; Takaki A; Yukawa C; Furusho M; Antoku S; Mifune M; Togane M
Diabetes Technol Ther; 2013 Jul; 15(7):586-90. PubMed ID: 23578166
[TBL] [Abstract][Full Text] [Related]
6. Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial.
Aronson R; Reznik Y; Conget I; Castañeda JA; Runzis S; Lee SW; Cohen O;
Diabetes Obes Metab; 2016 May; 18(5):500-7. PubMed ID: 26854123
[TBL] [Abstract][Full Text] [Related]
7. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes.
Garg SK; Paul JM; Karsten JI; Menditto L; Gottlieb PA
Diabetes Technol Ther; 2004 Oct; 6(5):589-95. PubMed ID: 15628812
[TBL] [Abstract][Full Text] [Related]
8. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
9. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.
Monami M; Marchionni N; Mannucci E
Diabetes Obes Metab; 2009 Apr; 11(4):372-8. PubMed ID: 19267715
[TBL] [Abstract][Full Text] [Related]
10. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
11. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
12. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
Vague P; Selam JL; Skeie S; De Leeuw I; Elte JW; Haahr H; Kristensen A; Draeger E
Diabetes Care; 2003 Mar; 26(3):590-6. PubMed ID: 12610006
[TBL] [Abstract][Full Text] [Related]
13. Glycaemic control and prevalence of hypoglycaemic events in children and adolescents with type 1 diabetes mellitus treated with insulin analogues.
Plavšić L; Mitrović K; Todorović S; Vuković R; Milenković T; Zdravković D
Vojnosanit Pregl; 2014 Sep; 71(9):817-20. PubMed ID: 25282778
[TBL] [Abstract][Full Text] [Related]
14. Functional intensified insulin therapy with short-acting insulin analog: effects on HbA1c and frequency of severe hypoglycemia. An observational cohort study.
Hartemann-Heurtier A; Sachon C; Masseboeuf N; Corset E; Grimaldi A
Diabetes Metab; 2003 Feb; 29(1):53-7. PubMed ID: 12629448
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction.
Lind M; Jendle J; Torffvit O; Lager I
Prim Care Diabetes; 2012 Apr; 6(1):41-6. PubMed ID: 22015237
[TBL] [Abstract][Full Text] [Related]
16. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
[TBL] [Abstract][Full Text] [Related]
17. HbA
Danne T; Cariou B; Banks P; Brandle M; Brath H; Franek E; Kushner JA; Lapuerta P; McGuire DK; Peters AL; Sawhney S; Strumph P
Diabetes Care; 2018 Sep; 41(9):1981-1990. PubMed ID: 29937431
[TBL] [Abstract][Full Text] [Related]
18. Does treatment with an insulin pump improve glycaemic control in children and adolescents with type 1 diabetes? A retrospective case-control study.
Brorsson AL; Viklund G; Örtqvist E; Lindholm Olinder A
Pediatr Diabetes; 2015 Nov; 16(7):546-53. PubMed ID: 25327782
[TBL] [Abstract][Full Text] [Related]
19. Insulin requirement profiles in Japanese hospitalized subjects with type 2 diabetes treated with basal-bolus insulin therapy.
Shimoda S; Okubo M; Koga K; Sekigami T; Kawashima J; Kukidome D; Igata M; Ishii N; Shimakawa A; Matsumura T; Motoshima H; Furukawa N; Nishida K; Araki E
Endocr J; 2015; 62(2):209-16. PubMed ID: 25392020
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
